Search
Research
Persistence of the immune responses and cross-neutralizing activity with Variants of Concern following two doses of adjuvanted SCB-2019 COVID-19 vaccineWe have previously reported the safety and immunogenicity four weeks after two doses of the Clover COVID-19 vaccine candidate, SCB-2019, a stabilized pre-fusion form of the SARS-CoV-2 S-protein (S-trimer). We now report persistence of antibodies up to 6 months after vaccination, and cross-neutralization titers against three Variants of Concern.
Research
An economic case for a vaccine to prevent group A streptococcus skin infectionsA vaccine that prevents GAS cellulitis and other skin infections, in addition to throat infections, would maximise its value and commercial viability
Research
Tuberculosis related disability: a systematic review and meta-analysisThe sustainable development goals aim to improve health for all by 2030. They incorporate ambitious goals regarding tuberculosis (TB), which may be a significant cause of disability, yet to be quantified. Therefore, we aimed to quantify the prevalence and types of TB-related disabilities.
Research
Excess respiratory mortality and hospitalizations associated with influenza in Australia, 2007-2015Influenza is the most common vaccine-preventable disease in Australia, causing significant morbidity and mortality. We assessed the burden of influenza across all ages in terms of influenza-associated mortality and hospitalizations using national mortality, hospital-discharge and influenza surveillance data.
Research
Transfluthrin eave-positioned targeted insecticide (EPTI) reduces human landing rate (HLR) of pyrethroid resistant and susceptible malaria vectors in a semi-field simulated peridomestic spaceVolatile pyrethroids (VPs) are proven to reduce human-vector contact for mosquito vectors. With increasing resistance to pyrethroids in mosquitoes, the efficacy of VPs, such as transfluthrin, may be compromised. Therefore, experiments were conducted to determine if the efficacy of transfluthrin eave-positioned targeted insecticide depends on the resistance status of malaria vectors.
Research
Clinical features and outcomes of COVID-19 and dengue co-infection: a systematic reviewDengue is the most common arboviral disease in the tropical and sub-tropical regions of the world. Like other regions, dengue-endemic areas have faced the additional public health and socio-economic impact of the ongoing coronavirus disease 2019 (COVID-19) pandemic.
News & Events
Infectious diseases advocate and child disability researcher named as finalists for national awardsCongratulations to prominent consumer advocate Catherine Hughes and The Kids Research Institute Australia honorary researcher Dr Noula Gibson, who have been named finalists in Research Australia’s 2023 Health and Medical Research Awards.
News & Events
Top honour for infectious diseases researchCongratulations to Associate Professor Asha Bowen, who has been awarded the 2022 Frank Fenner Award for Advanced Research in Infectious Diseases.
News & Events
The Kids Research Institute Australia Director elected to prestigious Australian Academy of ScienceProf Jonathan Carapetis has been elected as a new Fellow of the prestigious Australian Academy of Science in recognition of his pioneering, paradigm-shifting expertise in infectious diseases.
News & Events
New Co-directors for the Wesfarmers Centre of Vaccines and Infectious DiseasesDr Lea-Ann Kirkham and Dr Chris Blyth have been appointed as Co-Directors